title: Systemic lupus erythematosus: recent developments.
authors.forename: A M
authors.initials: AM
authors.lastname: Marmont
authors.forename: R
authors.initials: R
authors.lastname: Cerri
authors.forename: D
authors.initials: D
authors.lastname: Giordano
authors.forename: M
authors.initials: M
authors.lastname: Risso
authors.forename: L
authors.initials: L
authors.lastname: Cantú
authors.forename: L
authors.initials: L
authors.lastname: Grassia
authors.forename: A
authors.initials: A
authors.lastname: Queirolo
authors.forename: M R
authors.initials: MR
authors.lastname: Raffo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000906:Antibodies / Q000276:immunology*; D000974:Antibodies, Antinuclear / Q000276:immunology*; D001327:Autoimmune Diseases / Q000276:immunology* / Q000401:mortality / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000276:immunology*; D010951:Plasma Exchange; D011247:Pregnancy; D011248:Pregnancy Complications / Q000276:immunology; D015996:Survival Rate
chemical_list: D000906:Antibodies; D000974:Antibodies, Antinuclear; D010743:Phospholipids; D003520:Cyclophosphamide